Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016632 (Fox)
 1,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A tumour in an 11-year-old male crossbred Fox Terrier, showing the clinical and pathological features of epithelioid sarcoma in man is reported. Clinical aspects, location, peculiar pattern of spread and evolution, together with histopathological and immunohistological findings of this rare tumour simulating a granuloma are described. Controversial histogenesis is discussed.
 ...
PMID:Epithelioid sarcoma in a dog. 143 Mar 44

Over ten years, 70 patients with soft tissue sarcoma were treated for their primary tumors at the hospital of The Fox Chase Cancer Center. The clinical characteristics of these tumors are correlated with the outcome of various management efforts. The results of these evaluations identify three groups that can provide the basis for future treatment decisions and stratification for randomized studies of management options. The first group of patients, those with small well differentiated tumors, have no systemic spread regardless of the treatment modality used. The second group, those with large (greater than 5 cm) tumors that are moderately or poorly differentiated, do uniformly poorly despite the management techniques used. An intermediate group, those with high grade or large size but not both, have outcomes which may be correlated to treatment modalities.
 ...
PMID:Analysis of staging and management of patients with sarcoma: a ten-year experience. 736 14

Published studies of sarcomas using 31P MRS suffer from technical limitations that include absence of localization to regions of interest, resulting in heavy contamination with signals from muscle, and poor resolution. This review has shown that, in spite of their limitations, many of these studies provide important leads to indicate the directions that need to be taken to further develop clinical and biologic uses of MRS. The uniqueness of the metabolic information available in vivo in a noninvasive manner using MRS provides a major stimulus to pursue these directions. In particular, the potential of 31P MRS to predict treatment sensitivity and resistance in individual cases could lead to a very cost-beneficial clinical use of this procedure. 1H-decoupling and NOE-enhancement, implemented in conjunction with dual-tuned surface coils and accurate localization of 31P MR spectra to regions of interest in three dimensions using CSI, have enabled us to overcome the major technical limitations mentioned earlier, broaden the scope of 31P MRS investigations, and obtain more information about the in vivo metabolic characteristics of soft-tissue sarcomas than has heretofore been available. Our approach, which has been fully implemented in a clinical imager, provides a good technical basis from which to examine potential clinical uses of 31P MRS. In particular, we can now rigorously test the hypotheses, derived from preliminary studies in the literature, that initial metabolic features or early treatment-induced changes in PME predict sensitivity of a sarcoma to that particular treatment. To this end, we at Fox Chase Cancer Center, along with investigators at Duke University, the Institute of Cancer Research/Royal Marsden Hospital, Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, St. Georges Hospital Medical School, the University of California at San Francisco, and Wayne State University have initiated an NCI-sponsored cooperative trial to examine the role of 31P MRS in the clinical management of soft-tissue sarcomas and other selected cancers.
 ...
PMID:MR spectroscopy of musculoskeletal soft-tissue tumors. 856 91